News

A fingerprint of exhaled breath
Enlarge image

ResearchSwitzerland

A fingerprint of exhaled breath

04.04.2013 - Researchers from ETH Zurich have shown that the individual fingerprint of exhaled breath can be used for diagnostic purposes.

The team headed by Renato Zenobi reports in the journal PLoS that real-time analysis of the metabolic pattern found in exhaled breath can help to diagnose and monitor diseases. Using mass spectrometry (SESI-MS), the ETH researchers found that the chemical "fingerprint" of exhaled breath of 11 volunteers showed an individual core pattern and remained stable over time. According to the researchers, linking up that metabolic ID with genetic susceptibility to diseases can help diagnosing manifestation of diseases more individually. Shortly before, US researchers had published results of a MS-based study for diagnosis of heart failure

"We did find some small variations during the day, but overall the individual pattern stays sufficiently constant to be useful for medical purposes," says Pablo Martinez-Lozano Sinues, senior scientist in Zenobi's research group. To carry out these measurements, Zenobi and his colleagues modified commercial mass spectrometers by adding a breath sampling inlet line that delivers exhaled breath from a mouth piece directly into the ion source of the instrument. Mass spectra showing peaks of roughly 100 compounds in breath can be easily and rapidly obtained. 

The researchers are working to recognise characteristic patterns of lung diseases with the same technology. Although the potential usefulness of analysing breath for medical diagnosis has been known, it is rarely done in academic medicine. "This might be due to the fact that existing methods for breath analysis are either rather slow, or are limited to a small number of compounds that they can detect," says Sinues. Compared to analysis of blood or urine, a significant advantage of the ETH researchers’ approach is that the breath fingerprint is available within seconds. Another benefit is that exhaling into the ion source of a mass spectrometer is completely non-invasive. They researchers see huge potential to use the method as a tool for early detection of certain diseases in risk populations and in therapy monitoring.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/a-fingerprint-of-exhaled-breath.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ANALYTIK JENA14.00 EUR0.07%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.28 EUR0.00%
  • ACTELION112.60 CHF0.00%

TOP

  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%

TOP

  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR230.7%

FLOP

  • CYTOS1.40 CHF-53.0%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 28.03.2015